SG Americas Securities LLC Sells 7,740 Shares of Icon Plc $ICLR

SG Americas Securities LLC decreased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 48.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 8,222 shares of the medical research company’s stock after selling 7,740 shares during the period. SG Americas Securities LLC’s holdings in Icon were worth $1,439,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ICLR. Private Trust Co. NA boosted its holdings in Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 94 shares during the period. Ameritas Advisory Services LLC bought a new stake in shares of Icon during the second quarter worth $48,000. LRI Investments LLC purchased a new stake in shares of Icon during the second quarter valued at $49,000. Blue Trust Inc. boosted its stake in shares of Icon by 44.0% during the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 120 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Icon by 40,800.0% in the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock worth $59,000 after purchasing an additional 408 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ICLR shares. Cowen reiterated a “hold” rating on shares of Icon in a report on Friday, October 24th. Robert W. Baird set a $217.00 price target on shares of Icon in a research note on Friday, January 9th. UBS Group set a $220.00 price target on Icon in a report on Friday, October 24th. BMO Capital Markets assumed coverage on Icon in a report on Thursday, November 13th. They set a “market perform” rating and a $175.00 price objective on the stock. Finally, Barclays lifted their target price on Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $199.87.

Icon Stock Up 0.0%

Icon stock opened at $182.61 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $14.75 billion, a P/E ratio of 24.71, a P/E/G ratio of 3.84 and a beta of 1.26. The business has a fifty day moving average of $179.24 and a two-hundred day moving average of $174.01. Icon Plc has a twelve month low of $125.10 and a twelve month high of $211.00.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.